Literatur
-
1 European Medicines Agency .Press release October 25th, 2011
-
2
Gerlach H.
Einige Gedanken nach dem „Aus“ für
Xigris®.
Intensiv News.
2011;
15
6-8
-
3
Suter P M.
Xigris is withdrawn from the market. A 10 year odissey.
Minerva Anestesiol.
2011;
77
1128-1129
-
4
Bernard G R, Vincent J L, Laterre P F. et al .
Efficacy and safety of recombinant human activated protein C
for severe sepsis.
N Engl J Med.
2001;
344
699-709
-
5
Warren H S, Suffredini A F, Eichacker P Q, Munford R S.
Risks and benefits of activated protein C treatment for
severe sepsis.
N Engl J Med.
2002;
347
1027-1030
-
6
Abraham E, Laterre P F, Garg R. et al .
Drotrecogin alfa (activated) for adults with severe sepsis
and a low risk of death.
N Engl J Med.
2005;
353
1332-1341
-
7
Nadel S, Goldstein B, Williams M D. et al .
Drotrecogin alfa (activated) in children with severe sepsis:
a multicentre phase III randomised controlled trial.
Lancet.
2007;
369
836-843
-
8
Marx G.
Aktiviertes Protein C im septischen Schock – pro.
Dtsch Med Wochenschr.
2010;
135
2370
-
9
Graf J.
Aktiviertes Protein C im septischen Schock –
contra.
Dtsch Med Wochenschr.
2010;
135
2371
-
10
Mitka M.
Drug for severe sepsis is withdrawn from market, fails to
reduce mortality.
JAMA.
2011;
306
2439-2440
-
11
Eichacker P Q, Natanson C, Danner R L.
Surviving sepsis – practice guidelines, marketing
campaigns, and Eli Lilly.
N Engl J Med.
2006;
355
1640-1642
-
12
Boomer J S, To K, Chang K C. et al .
Immunosuppression in patients who die of sepsis and multiple
organ failure.
JAMA.
2011;
306
2594-2605
-
13
Kumar G, Kumar N, Taneja A. et al .
Nationwide trends of severe sepsis in the 21st century
(2000 – 2007).
Chest.
2011;
140
1223-1231
-
14
Harrison D A, Welch C A, Eddleston J M.
The epidemiology of severe sepsis in England, Wales and
Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical
database, the ICNARC Case Mix Programme Database.
Crit Care.
2006;
10
R42
-
15
Castellanos-Ortega A, Suberviola B, Garcia-Astudillo L A. et al .
Impact of the Surviving Sepsis Campaign protocols on hospital
length of stay and mortality in septic shock patients: results of a three-year
follow-up quasi-experimental study.
Crit Care Med.
2010;
38
1036-1043
Prof. Dr. Hans-Georg Bone
Klinik für Anästhesiologie und
Intensivmedizin
Klinikum Vest
GmbH
Behandlungszentrum
Knappschaftskrankenhaus
Recklinghausen
Dorstener Str. 151
45657 Recklinghausen
Email: bone.hans-georg@kk-recklinghausen.de
